StockEarnings.com

Is Starlink Set For The Largest IPO In History? (ad)

Dear Fellow Trader,

I hope this trading day has been good to you! I am sending you trade ideas for tomorrow. So you can have enough time to take action on our trades ideas.

What’s going on in this strange facility near Mar-a-Lago? (ad)
Most people have no clue this unassuming facility exists. But now that Donald Trump has officially taken office... This could be the most important building in America over the next 100 days. More important than the Capital, the Pentagon... even the White House. Because this may well be the epicenter of Trump’s New Manhattan Project.
👉 Click here for more details.

Options Trade Ideas (Volatility Rush Strategy)

The basic option trade idea is to buy an at-the-money straddle while the options premium is cheap.

In assessing this trade, you need to do your homework to ensure you are not paying too much for the straddle.

As the earnings date approaches, the implied volatility (IV) should increase, resulting in greater price movement.

However, be aware that you should close your position before the announcement comes out in order to maximize your profit potential. That's because once earnings are released, IV will fall dramatically, which will greatly reduce your opportunity to profit on the trade.

The stocks (with Weekly Options) below are announcing earnings in next few weeks. Our proprietary volatility algorithm suggests these stocks are likely to experience high volatility as earnings day approaches.

Symbol Company	Earning Date	Predicted Volatility ^*
CMG	02/04	6%
MSTR	02/04	5%
NET	02/06	9%
GOOS	02/06	11%
ABNB	02/11	7%
TWLO	02/12	11%
PINS	02/13	8%
TDOC	02/18	9%
LCID	02/19	10%
NVDA	02/19	5%
DKNG	02/20	6%
M	02/25	6%
BIDU	02/26	5%
ADSK	03/06	5%
Click Here to View Your Full Report

Before Market Open

After Market Close

*Predicted Volatility % based on our Proprietary Volatility Predication Model. We are expecting that stock price will likely to reach % in either direction by the end of next trading session after Earnings are released and not necessarily the closing volatility %.

The Public Safety Revolution 🚀 (ad)*
One company is leading the charge with cutting-edge tech and a low-cost service model.
With growing momentum and a tight stock float, this is one to watch. 👉 Click here to get the Full Story!

Why January 31st Will Impact Stocks More Than The Election (This happens only once every 25 years.) (ad)
A man from a completely different government branch is going to stand up, say a few words… … and make history in the stock market. This event comes along only every 25 years… And experts are already positioning themselves to profit from it.
👉 Click here for the full story.

At StockEarnings, we're really excited to help you trade more confidently. To that end, we’re constantly developing new content to go alongside our platform insights, which will further our mission to help you become a better trader.

To your trading success,

Hiral Ghelani

Founder & CEO

StockEarnings, Inc

33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA

W: 877.6.STOCKS (Mon to Sat | 9am to 5pm EST | Feel Free to Call Us)

ALERT: 3 stocks under $20 partnered with Netflix, Honda & more.

Just identified: 3 innovative players partnered with household names like Netflix and Honda - yet still trading below $20. Plus, one has $196M in government contracts.

Click here to get these picks (totally free)

(ad)* This message is a PAID ADVERTISEMENT for Knightscope, Inc. (NASDAQ:KSCP) from Market Jar Media Inc. StockEarnings, Inc. has received a fixed fee of $6,000 from Market Jar Media Inc. for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between January 23, 2025 and January 29, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either Knightscope, Inc. (NASDAQ:KSCP) or Market Jar Media Inc. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Knightscope, Inc. (NASDAQ:KSCP) on UpAlpha website for additional information about the relationship between Market Jar Media Inc. and Knightscope, Inc. (NASDAQ:KSCP).

(ad)** This message is a PAID ADVERTISEMENT for InMed Pharmaceuticals (NASDAQ:INM) from i2i Marketing Group, LLC. StockEarnings, Inc. has received a fixed fee of $5,000 from i2i Marketing Group, LLC for multiple Newsletter Sponsorships Sends between January 21, 2025 and January 27, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either InMed Pharmaceuticals (NASDAQ:INM) or i2i Marketing Group, LLC. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding InMed Pharmaceuticals (NASDAQ:INM) on Edge on the street website for additional information about the relationship between i2i Marketing Group, LLC and InMed Pharmaceuticals (NASDAQ:INM).

StockEarnings, Inc (SE) is a research service not owned or managed by registered brokers and therefore this site does not make any investment recommendations. The information provided in this newsletter is not guaranteed as to the accuracy or completeness. Each user of SE chooses to do trades at their sole discretion and risk. SE is not responsible for gains/losses that may result in the trading of these securities.

This newsletter includes paid advertisements. The source of all third-party content in which SE receives some sort of compensation, is clearly and prominently identified herein as "ad" or "Sponsored". Although we have sent you these advertisements, SE does not specifically endorse any third-party product nor is it responsible for the content of the advertisement or the experience with the third-party advertiser. Furthermore, we make no guarantee or warranty about what is advertised.

All investments involve risk, losses may exceed the principal invested, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. Please click here for SE Disclaimers.

Unsubscribe

Today's Bonus Content: Do this Before Elon’s Reveal on January 29th